Profile gets US nod for inhaled therapies technology:
This article was originally published in Clinica
Executive Summary
UK firm Profile Therapeutics has received US FDA approval to sell its second-generation adaptive aerosol delivery (AAD) system, Prodose. The product is already available in Europe to deliver Promixin, an inhaled antibiotic for treating patients with cystic fibrosis, and Ventavis, Schering AG's product for pulmonary hypertension. It has also been selected regarding the development of CoTherix' inhaled Iloprost for pulmonary hypertension. A third-generation system, Prodose HandHeld, is in its final stages of development and is expected to be available to patients this year, said Bognor Regis, West Sussex-based Profile Therapeutics. The company is currently in discussions regarding an offer being made for the firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.